Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy

Authors

Kang Qin
Kaiwen Wang
Shenduo Li
Lingzhi Hong
Priyadharshini Padmakumar
Rinsurongkawong Waree
Shawna M Hubert
Xiuning Le
Natalie Vokes
Kunal Rai
Ara Vaporciyan
Don L Gibbons
John V Heymach
J Jack Lee
Scott E Woodman
Caroline Chung
David A Jaffray
Mehmet Altan
Yanyan Lou
Jianjun Zhang

Publication Date

2-26-2024

Journal

Cancers

Abstract

Docetaxel +/- ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/- ramucirumab. We also investigated whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. A total of 454 patients were analyzed (docetaxel +/- ramucirumab n=381; platinum/taxane-based regimens n=73). Progression-free survival (PFS) and overall survival (OS) were compared among different subpopulations with different cancer gene mutations and between patients who received docetaxel +/- ramucirumab versus platinum/taxane-based regimens. Among patients who received docetaxel +/- ramucirumab, the top mutated cancer genes included TP53 (n=167), KRAS (n=127), EGFR (n=65), STK11 (n=32), ERBB2 (HER2) (n=26), etc. None of these cancer gene mutations or PD-L1 expression was associated with PFS or OS. Platinum/taxane-based regimens were associated with a significantly longer mQS (13.00 m, 95% Cl: 11.20-14.80 m versus 8.40 m, 95% Cl: 7.12-9.68 m, LogRank P=0.019) than docetaxel +/- ramcirumab. Key prognostic factors including age, histology, and performance status were not different between these two groups. In conclusion, in patients with metastatic NSCLC who have progressed on platinum doublets and ICIs, the clinical benefit from docetaxel +/- ramucirumab is not associated with the cancer gene mutation status. Platinum/taxane-based regimens may offer a superior clinical benefit over docetaxel +/- ramucirumab in this patient population.

Keywords

metastatic non-small-cell lung cancer, docetaxel with or without ramucirumab, platinum–taxane

Comments

Supplementary Material

PMID: 38473297

DOI

10.3390/cancers16050935

PMID

38473297

PMCID

PMC10931294

PubMedCentral® Posted Date

February 2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes